CytoMed Therapeutics Limited

US$0.86As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GDTCHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR (32.02%)
Div yield —
ROE (56.17%)
Biotechnology
Beta (5Y) 0.02
PE TTM —
TSR TTM (60.95%)
Mkt cap US$10.25M
ROIC (36.85%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.976
13.58%
206.58%
Hold 0|7|4|5|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
10.32%
7.48%
13.78%
8.50%
Revenue$M
0.683
0.701
0.741
0.779
9.03%
7.87%
10.24%
13.74%
Peers (US$10.25M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
21.77
(0.242)
(0.238)
EBIT/Intx
0.258
0.118
0.125
Own earn%
(32.77)
(35.73)
(27.18)
Sh yield%
31.15
34.39
28.16
Owners
Insiders/Inst%
5.42
31.10
Short interest%
4.16
SBC / revenue%
2.80
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
0–4
$1 testx
0.0
Incr. ROIC%
1